Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by equities researchers at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Wednesday, The Fly reports. The analysts noted that the move was a valuation call.
Other equities research analysts also recently issued reports about the company. Wedbush restated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Friday, May 18th. Zacks Investment Research downgraded Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. Cantor Fitzgerald restated a “hold” rating and issued a $58.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, May 8th. Oppenheimer set a $100.00 target price on Intercept Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, August 2nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, August 2nd. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $117.67.
ICPT opened at $111.65 on Wednesday. The company has a market capitalization of $3.36 billion, a price-to-earnings ratio of -7.76 and a beta of -1.68. The company has a debt-to-equity ratio of 2.48, a current ratio of 6.51 and a quick ratio of 6.51. Intercept Pharmaceuticals has a 1-year low of $51.05 and a 1-year high of $121.92.
Large investors have recently made changes to their positions in the company. US Bancorp DE lifted its position in shares of Intercept Pharmaceuticals by 821.6% during the 1st quarter. US Bancorp DE now owns 1,751 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 1,561 shares during the last quarter. Tocqueville Asset Management L.P. acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at $252,000. Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at $264,000. United Services Automobile Association acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at $280,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at $282,000. Institutional investors own 66.63% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Featured Article: Understanding Analyst Recommendations
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.